Business
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine
Based on FDA Office of Generic Drugs guidance previously announced, NRx has transmitted an initial GMP manufacturing order to its US-based manufacturer.NRx has completed confirmatory GMP audits of manufacture and is prepared for pre-approval inspection.Initial manufacture rate is sufficient to support significant market penetration in first year sales and can be readily scaled based on blow-fill-seal manufacturing process. WILMINGTON, Del., May 05, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, I
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"image","alt":"NRx Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"NRx Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/4ef53875d129fcc14f2614dd5795d5a9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oQlnKXAw77IR4.RQxkfHUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/4ef53875d129fcc14f2614dd5795d5a9","width":300,"height":300}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Based on FDA Office of Generic Drugs guidance previously announced, NRx has transmitted an initial GMP manufacturing order to its US-based manufacturer.","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"NRx has completed confirmatory GMP audits of manufacture and is prepared for pre-approval inspection.","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Initial manufacture rate is sufficient to support significant market penetration in first year sales and can be readily scaled based on blow-fill-seal manufacturing process.","length":173,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":426,"olType":false},{"type":"text","content":"WILMINGTON, Del., May 05, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces initiation of a first commercial manufacturing order of its preservative free ketamine product in anticipation of approval under the Generic Drug User Fee Act in Summer 2026. The order is based on stability observed in more than 3 manufactured registration batches and the Company’s successful third-party audit of the manufacturing facility.","length":564,"tagName":"p"},{"type":"text","content":"The Company expects that the initial manufacturing pace will be sufficient to support initial substantial yearly revenues and notes the ability to rapidly scale manufacturing as demand grows. The Company recently announced the appointment of Mr. Glenn Tyson as its Chief Commercial Officer and is in the process of retaining a full commercial team.","length":348,"tagName":"p"},{"type":"text","content":"The NRx product is the first US-manufactured preservative-free ketamine presentation. Manufacturing...